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Background: In humans and animals, prion protein (PrP) is usually expressed as a glycophosphatidylinositol
(GPI)-anchored membrane protein, but anchorless PrP may be pathogenic in humans with certain familial prion
diseases. Anchored PrP expressed on neurons mediates spread of prions along axons in the peripheral and central
nervous systems. However, the mechanism of prion spread in individuals expressing anchorless PrP is poorly
understood. Here we studied prion spread within brain of mice expressing anchorless or anchored PrP.
Results: To create a localized initial point of infection, we microinjected scrapie in a 0.5 microliter volume in the
striatum. In this experiment, PrPres and gliosis were first detected in both types of mice at 40 days post-inoculation
near the needle track. In mice with anchored PrP, PrPres appeared to spread via neurons to distant connected brain
areas by the clinical endpoint at 150 days post-inoculation. This PrPres was rarely associated with blood vessels. In
contrast, in mice with anchorless PrP, PrPres spread did not follow neuronal circuitry, but instead followed a novel
slower pattern utilizing the drainage system of the brain interstitial fluid (ISF) including perivascular areas adjacent
to blood vessels, subependymal areas and spaces between axons in white matter tracts.
Conclusions: In transgenic mice expressing anchorless PrP small amyloid-seeding PrPres aggregates appeared to
be transported in the ISF, thus spreading development of cerebral amyloid angiopathy (CAA) throughout the brain.
Spread of amyloid seeding by ISF may also occur in multiple human brain diseases involving CAA.
Keywords: Brain interstitial fluid, Cerebral amyloid angiopathy, Prion, Glycophosphatidylinositol anchor, Basement
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Prion protein (PrP) is a host-encoded membrane glyco-
protein expressed in many tissues and cell types. The
normal functions of PrP are not known, and PrPnull
mice are for the most part clinically normal [1,2]. How-
ever, with sophisticated testing, PrPnull mice have de-
tectable deficits in both neurophysiological and memory
functions (for review see [3]). These functions appear to
be related to the function of PrP in neurons because
they can be reversed by expression of PrP in neurons
using a neuron-specific transgene [4].* Correspondence: bchesebro@nih.gov
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stated.The most striking function of PrP to date is the abso-
lute requirement for PrP expression for susceptibility of
animals to prion infection and disease [1]. Disease-
associated partially protease-resistant PrP (PrPres) is
believed to be the infectious agent responsible for trans-
mission between individuals [5-7], and the endogenous
host PrP appears to interact with PrPres providing a
substrate for new PrPres conversion [8]. In addition,
host cellular PrP appears to be involved in transport of
prion infectivity along peripheral nerves leading to the
CNS [9-15] as well as along neuroanatomical pathways
within the CNS such as the optic tract with multiple
neurons and synapses leading from retina to the superior
colliculus and optic cortex [14,16,17]. PrP expression on
neurons or astrocytes is sufficient to meditate suscepti-
bility and neuroinvasion by prion infectivity [17-20].
However, PrP expression on other cell types such asLtd. This is an Open Access article distributed under the terms of the Creative
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ity to prion infection [21].
Although prion protein (PrP) is expressed mainly as
a glycophosphatidylinositol (GPI)-anchored membrane
protein, anchorless PrP is found in certain humans with
familial prion disease and can be associated with
pathology involving perivascular deposition of amyloid
PrPres resulting in cerebral amyloid angiopathy (CAA)
[22-26]. Expression of anchorless PrP in transgenic mice
(tg44), results in susceptibility to intracerebral (i.c.) scra-
pie infection with replication of high scrapie infectivity
titers and amyloid PrPres deposition in brain, heart, fat,
colon, muscle and liver [27]. In brain there is extensive
deposition of amyloid PrPres around blood vessels pro-
ducing CAA pathology and clinical disease by 300–350
dpi [28]. This scrapie incubation period is much longer
than the 150–160 day incubation period seen in C57BL/
10SnJ (C57) mice expressing anchored PrP, which have
vacuolar gray matter pathology and non-amyloid PrPres
deposition, which is not associated with blood vessels
[28]. The different incubation times and pathology seen
after scrapie infection in mice expressing anchored ver-
sus anchorless PrP might be explained by differences in
various aspects of the disease process including: first,
different toxicity of amyloid and non-amyloid forms of
prions; second, different susceptibility of mice to prion
infection or damage; third, different ability to spread the
infection to CNS locations resulting in clinical disease.
In the present paper we describe experiments aimed at
testing the latter two of these possibilities.
To investigate whether tg44 mice and C57 mice dif-
fered in susceptibility to scrapie infection, we compared
these mouse strains in a limiting dilution titration of
scrapie infectivity using i.c. injections. Surprisingly, the
endpoint titer for scrapie infectivity in these two mouse
strains was indistinguishable, suggesting that they were
equally susceptible to the infection.
As another potential explanation for the difference in
disease tempo in these mice, we next studied spread of
scrapie PrPres within brain after intracerebral injection
of each mouse strain. Previously we showed an associ-
ation at the time of clinical disease between PrPres
amyloid and the ISF drainage system using ISF tracers
[29]; however, in this work we did not look at multiple
preclinical time-points to determine the localization and
pattern of spread of the PrPres amyloid over time. Be-
cause of the very poor spread of PrPres in peripheral
nerves after intranerval injection of mice expressing an-
chorless PrP [30], we hypothesized that in brain of tg44
mice PrPres might not spread via neuroanatomical con-
nections as seen in C57 mice. Two possibilities were
considered: First, mechanical dissemination of PrPres ag-
gregates capable of seeding new PrPres conversion might
occur mostly at the time of intracerebral (i.c.) injection.Subsequent slow outgrowth of plaques from sites of
original seed deposits would occur, but there might be
negligible additional dissemination of new seeds. Alter-
natively, PrPres amyloid might spread continuously
throughout the disease course via a slow pathway which
did not require expression of anchored PrP on cell sur-
faces [31]. To limit the initial mechanical spread of the
inoculum, we infected mice using intracerebral (i.c.)
microinjection of scrapie in a small volume (0.5 μl),
and at various times we studied the spread of PrPres
throughout the brain by immunohistochemical evalu-
ation. The results showed striking differences between
mice expressing anchorless PrP versus anchored PrP,
suggesting that unique mechanisms of spread of PrPres
occurred in mice expressing anchorless PrP.
Methods
Ethics statement
All mice were housed at RML in an AAALAC-accredited
facility in compliance with guidelines provided by the
Guide for the care and use of Laboratory Animals (Insti-
tute for Laboratory Animal Research Council). Experi-
mentation followed Rocky Mountain Laboratory Animal
Care and Use Committee approved protocols 2010–08
and 2011–04.
Mice
Transgenic mice were homozygous tg44+/+ mice ex-
pressing two alleles of a transgene encoding mouse prion
protein lacking the GPI anchor on a genetic background
of C57BL/10SnJ as described previously [28]. Mice were
bred at RML. C57BL/10 mice were obtained from Harlan
Sprague Dawley, Kent. WA, USA.
Scrapie titration
To study sensitivity to mouse-adapted scrapie strain
RML, mice from 4–6 weeks of age were inoculated in-
tracerebrally with serial 10-fold dilutions from 10-2 to
10-9 in a volume of 50 μl. For intracerebral inoculation,
mice were anaesthetized with isoflurane and injected
manually in the left parietal lobe with a 27-gauge, 0.5-
inch needle. Animals were observed daily for onset and
progression of scrapie using previously described criteria
[28]. The duration of disease varied from 30–60 days
which was consistently longer than the duration noted
in C57BL/10SnJ mice with anchored PrP. Typically in
scrapie-infected Tg44+/+ mice, defective nesting was the
first clinical sign. This was followed by hind limb weak-
ness and a wide-based gait with low body posture. At
later times severe hypoactivity and somnolence were
noted. This condition was predictive of death within
1–2 days, and was designated as advanced clinical dis-
ease. Mice were euthanized when such signs were noted.
Brains were removed and divided sagittally. One half
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future use in western blot analyses, and the other half
was immersed in 10% neutral buffered formalin (3.7%
formaldehyde) for histology.
Intracerebral injection of FluoSpheres
In order to determine the extent of dispersion of a 50 μl
injection into the brain of young mice, we injected 5
week old C57BL/10 mice intracerebrally with 50 μl of
1% (w/v) red fluorescent carboxylate-modified micro-
spheres (0.02 μm; 580/505) (FluoSpheres, Molecular
Probes, Eugene, OR). Mice were injected in the left par-
ietal lobe. Other mice were microinjected stereotactically
with 0.5 μl of FluoSpheres in the striatum. Five or
30 min after inoculation mice were anaesthetized with
isoflurane, and then perfused intracardially with 0.1 M so-
dium phosphate buffer, pH 7.4 with heparin (30 units/ml)
followed by 4% paraformaldehyde, adjusted to pH 7.3 by
addition of NaOH. Brains were removed, post-fixed over-
night in the same fixative, and cryoprotected in 30%
sucrose in phosphate-buffered saline (PBS) without Mg+2
or Ca+2 for 48 h. Ten sagittal sections (20 μm thickness)
were cut through the entire brain from the middle line
using a cryostat (Leica, Richmond, IL, USA). Sections were
placed on positively charged glass slides, and then air-
dried overnight. Slides were hydrated in distilled H2O, and
coverslips were applied to tissue sections using a mount-
ing medium of Prolong Gold anti-fade reagent with DAPI
reagent (Invitrogen).
Stereotaxtic surgery
Intracerebral microinjections of 1% (w/v) RML brain
homogenate stock were performed on adult male mice
that weighed approximately 30 g. Age-matched trans-
genic tg44 and non-transgenic C57BL/10 mice were also
injected with normal brain homogenate (NBH) in some
experiments. Mice were anaesthetized with isoflurane
and positioned on a stereotaxic frame (David-kopf
Instruments, Tujunga, CA, USA). A 1-cm midline inci-
sion was made in the skin over the dorsal surface of the
skull, and the skull was exposed to allow positioning
of the drill over the Bregma point of reference. Co-
ordinates used from Bregma were, +1 mm anteroposter-
ior, +1.7 mm lateral and −3 mm ventral to skull surface.
These co-ordinates were selected to target the center of
the left striatum and avoid passing through any ventricle.
Brain homogenates were injected with Nanofil syringes
(World Precision Instruments, Sarasota, FL, USA) and
steel bevel needles (32-gauge diameter) (World Precision
Instruments) into the striatum at a rate of 0.25 μl/min
with a total of 0.5 μl per mouse controlled with a pump
(UltraMicroPump III with Micro4 pump controller,
World Precision Instruments). The needle was kept in
place for 2 min following injection to avoid the reflux ofthe brain homogenate solution. The skin incision was
closed with suture. These conditions produced minimal
brain damage and high reproducibility. Patency of the
needles was verified prior to and after injections. Mice
were euthanized by anesthesia overdose at different
times after injection.
Histology
Brains were removed and placed in 10% neutral buffered
formalin for 3 to 5 days. Whole brains were divided cor-
onally into 4 regions: (1) olfactory bulb to Bregma in-
cluding the entire striatum, (2) middle thalamic area, (3)
midbrain and (4) cerebellum. These tissues were then
processed by dehydration and embedding in paraffin.
The block including the striatum was cut into 5 μm cor-
onal sections through the entire striatum region. Five
adjacent sections were saved from each 75 μm linear re-
gion. One section from each group was stained by H&E
to determine the needle track location. Additional sec-
tions from the other three areas (thalamus, midbrain
and cerebellum) were obtained from mice at various
time-points as needed. In early experiments each whole
brain was embedded as a single block and 10 μm sec-
tions were cut, saving 4–5 adjacent sections out of each
100 μm distance. Sections were cut using a standard
Leica microtome, placed on positively charged glass
slides, and air-dried overnight at room temperature. The
following day slides were heated in an oven at 60°C for
20 min and were then deparaffinized and rehydrated to
aqueous conditions using standard procedures.
Immunohistochemical detection of PrPres, GFAP and Iba1
Antigen retrieval and staining was performed using the
Ventana automated Discovery XT stainer. PrP antigens
were exposed by incubation in CC1 buffer (Ventana)
containing Tris-Borate-EDTA, pH 8.0 for 100 minutes at
95°C. Staining for PrP was done using human anti-PrP
monoclonal antibody D13 [32], which was obtained from
tissue culture supernatants made in our laboratory from
CHO cells expressing the D13 antibody construct, which
were kindly provided by Dr. R. Anthony Williamson,
The Scripps Research Institute, La Jolla, CA [29]. For
immunohistochemistry, D13 culture fluid was used at a
dilution of 1:100 for 2 hours at 37°C. The secondary
antibody was biotinylated goat anti-human IgG at 1:500
dilution (Jackson ImmunoResearch, West Grove, PA.),
and avidin-horseradish peroxidase was used with DAB
as chromogen (DAB Map kit; Ventana Medical Systems,
Tucson, AZ.).
Rabbit anti-Iba1 (Wako, Richmond, VA, USA) (dilution
1:2000), and rabbit anti-glial fibrillary acidic protein
(GFAP) polyclonal antibody (1:3500) (Dako) were used.
Antigen retrieval was done using CC1 buffer at 95°C for
44 min (Iba1) or 60 min (GFAP). Primary antibodies were
Figure 1 Limiting dilution titration of RML scrapie in tg44 and
C57 mice. Serial ten-fold dilutions of RML scrapie were inoculated
i.c. in a volume of 50 μl into either tg44 (squares) or C57 (circles)
mice. Each point indicates the incubation period for one mouse; in
cases of overlap the symbols have been separated to facilitate obser-
vation. Solid symbols indicate mice that had clinical signs and de-
tectable PrPres in their brains. Open symbols indicate mice that did
not develop disease or detectable levels of PrPres in brain. Using the
data shown, the calculated titers for RML scrapie were: tg44 mice,
108.1 ID50/gram of brain and C57 mice,107.9 ID50/gram of brain.
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Triton X-100. Diluent without antibody was used as a
negative control. Ventana streptavidin-alkaline phosphat-
ase protocol was used to detect Iba1 and GFAP as de-
scribed previously [33] with the exception that Fast Red
chromogen was used. Slides were examined and photomi-
crographs were taken observed using an Olympus BX51
microscope and Microsuite FIVE software.
Immunofluorescence staining
Slides were stained using the Dako Autostainer Plus ma-
chine (Dako, Carpentaria, CA, USA). Sections were perme-
abilized with PBS without Mg+2 or Ca+2 with 0.1% Triton
X-100 for 15 min and blocked in 1% normal goat serum
and 0.1% Triton X-100 in PBS for 15 min, followed by three
5 min rinses with PBS. For antigen retrieval of sections
double-stained for PrPres plus CD31 or APP, tissue sections
were soaked in citrate buffer, pH 6.0, and heated to 120˚C
at 20 lb/in2 for 20 min using a BioCare decloaking cham-
ber. For immunofluorescence staining, D13 supernatant
was used at a 1:500 dilution, polyclonal rat anti-endothelial
cell marker (CD31) antibody was used at a 1:50 dilution
(Dianova, GmbH, Hamburg, Germany), and polyclonal
rabbit anti-amyloid precursor protein (APP) was used at a
1:25 dilution (Invitrogen). Both primary antibodies were
co-incubated for one hour at room temperature. This was
followed by three 5 min rinses with PBS. Slides were then
co-incubated with Alexa-Fluor 488 goat anti-rabbit Ig and
Alexa-Fluor 568 goat anti-human Ig (Invitrogen, Carlsbad,
CA) for 30 min at room temperature. Both secondary anti-
bodies were used at a 1:200 dilution. Slides were next rinsed
with double-distilled H2O, and coverslips were applied to
tissue sections with ProLong Gold antifade reagent with
4’,6’-diamidino-2-phenylindole (DAPI; Invitrogen) to stain
nuclei and protect fluorescence from fading. Diluent with-
out primary antibody was used as a negative control. The
staining was observed using an Olympus BX51 microscope
using Microsuite FIVE software.
Slide scanning
Aperio Digital Pathology Systems (Aperio Technologies,
Vista, CA) was used to scan, capture, and store whole slide
images from sagittal and coronal histology samples. Slides
were scanned with the ScanScope® XT at 20× magnifica-
tion for immunohistochemistry and ScanScope® FL for im-
munofluorescent samples. ImageScope™ software (Aperio
ImageScope v10.1.3.2028) was used to view and export
e-slide images in JPEG format.
Results
Comparison of limiting dilution scrapie titration in C57
versus tg44 mice
In previous experiments i.c. injection of tg44 mice with
106 ID50 of scrapie strains 22 L or RML resulted inclinical neurological disease at 300-350dpi, which was
twice as long as the incubation period seen in non-
transgenic C57 mice [28]. This might be explained by a
difference between these mice in susceptibility to infec-
tion. To address this question in the present experi-
ments, these mouse strains were compared by limiting
dilution infection using a brain homogenate stock of
RML scrapie made from C57 mice (Figure 1). Incubation
period times were the time to advanced clinical disease,
and the diagnosis of scrapie was confirmed by immuno-
blot detection of PrPres in brain. Nearly identical end-
point dilution titers of 108.1 and 107.9 ID50/gram of brain
in tg44 and C57 mice respectively were calculated from
these data, indicating that these mice did not differ in sus-
ceptibility to scrapie infection. However, the tg44 mice
had incubation periods which were 150–300 days longer
than those seen in the C57 mice at each infectivity level
tested (Figure 1). This difference appeared to correlate
with the different types of pathogenesis induced by scrapie
infection in these two types of mice [28].
In tg44 mice after inoculation of scrapie brain hom-
ogenate dilutions of 10-3 and 10-4, the time of clinical
disease was 330–395 dpi (Figure 1), and immunohisto-
chemical detection of PrPres in these mice revealed
widespread plaques in most brain regions (Figures 2a
and 2b). However, after inoculation of dilutions of 10-5
or 10-6,where the clinical endpoint was 458–601 dpi
(Figure 1), fewer PrPres plaques were detected, and they
were located mainly on meningeal and ependymal sur-
faces (Figures 2c and 2d). Since these areas are bathed in
cerebrospinal fluid (CSF), these results suggested that a
Figure 2 Immunohistochemistry for PrPres in brains of tg44 mice following inoculation with different dilutions of RML scrapie. Panels
a-e show PrPres staining (brown) using anti-PrP antibody D13. Mice shown in panels a-d had clinical signs consistent with prion infection,
whereas mouse in panel e did not have clinical signs and was euthanized at the end of the experiment (668 dpi). The dilution of inoculum and
day of euthanasia for each panel are as follows: a: 10-3, 371 dpi; b: 10-4, 382 dpi; c: 10-5, 480 dpi; d: 10-6, 528 dpi; e: 10-7, 668 dpi.
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might have been initiated by infectivity entering the
cerebrospinal fluid (CSF) at the time of injection,
rather than by the injection into the brain paren-
chyma itself.Figure 3 Detection of 0.02 μm Fluospheres in brain at 30
minutes after i.c. injection. (a) Injection of a 50 μl inoculum with
a hand-held syringe. Pink Fluospheres were detected in ventricular
(v) walls (yellow arrow) and on meninges (green arrows), but were
not detected in brain parenchyma. (b) Microinjection of a 0.5 μl
inoculum. Pink Fluospheres were detected in striatum and corpus
callosum (yellow arrows), but not in ventricles (v) or on meninges
(green arrowhead). Scale is same in each panel, and bar represents
500 μm.Brain spread of i.c. injected FluoSpheres
The large injection volume (50 μl) used in the preceding
experiments might result in spillover of the inoculum
into the CSF during the injection. To test this possibility,
FluoSpheres (size = 0.02 μm) were injected i.c. using
either a 50 μl volume in a hand-held syringe or in a
0.5 μl volume using a microinjection method with a
constant pressure pump over a 2 min period. Mice were
euthanized 30 min post-injection for microscopic exam-
ination of brain tissue. After the 50 μl injection, Fluo-
Spheres were mainly found associated with meningeal
and ependymal surfaces (Figure 3a). In contrast, after
microinjection of 0.5 μl, FluoSpheres were detected
only within the brain parenchyma (Figure 3b). Similar
results were seen in mice euthanized at 5 min post-
injection. These data supported the interpretation that
at the time of i.c. injection of a 50 μl volume the
scrapie inoculum might easily contaminate the CSF
leading to infection of meningeal and ependymal sur-
faces of the brain as was observed above in Figures 2c
and 2d.Perivascular and extracellular spread of scrapie infection
in CNS of tg44 mice
Based on the preceding experiments, to study the spread
of scrapie infectivity within the CNS more precisely, we
infected mice i.c. using stereotaxic microinjection into
the striatum using a 0.5 μl volume of scrapie brain
Figure 4 (See legend on next page.)
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Figure 4 Time course analysis of distribution of PrPres plaques in brain after microinjection of RML scrapie. Panels a-e show detection
of PrPres by Mab D13 in coronal sections of whole brain at the level of the needle track. (a) 40 dpi, PrPres plaques in needle track area of cortex
are circled. (b) 81 dpi, several groups of plaques in cortex, striatum and adjacent subependymal area are circled. (c) 160 dpi, a larger area of PrPres
staining can be seen in needle track region and neighboring areas from meningeal surface to striatum. Several groups of more isolated plaques
can also be seen in adjacent areas. One plaque (arrow) is seen in cortex on contralateral side. (d) 213 dpi, numerous plaques are seen on both
sides of brain, more in dorsal areas. Some streaked plaque staining can also be seen in the corpus callosum at higher magnification (arrowheads).
(e) 320 dpi, plaques are found in most regions, but fewer plaques are seen in central ventral areas and in ventral cortex on contralateral side. At
higher magnification streaming plaques in the corpus callosum can also be seen (arrowheads). (f) High power view of single perivascular plaque
in cortex at 40 dpi from same mouse as panel a. Central blood vessel is shown by arrow. (g) Group of subependymal plaques (arrows) from same
mouse as shown in panel b. (h) Single plaque with prominent vessel (arrow) at interface of corpus callosum and striatum at 81 dpi. (i) PrPres in
corpus callosum associated with blood vessels (arrows) which are near to PrPres apparently streaming along interaxonal spaces (arrowheads). (j)
Large plaque and adjacent small plaques in cortex with higher density of PrPres surrounding blood vessels (arrows). Scale bars are as follows: f, h,
i, j = 50 μm; g = 100 μm.
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mice developed advanced clinical signs between 307–336
dpi. To study spread of scrapie within the brain, mice were
euthanized at multiple time points, and coronal sections
of the area of the striatum and other regions were studied
by H&E staining for histopathology and by D13 anti-PrP
staining using immunohistochemistry.
After microinjection of scrapie, PrPres amyloid pla-
ques were first seen at 40 dpi at the site of the needle
track in the cerebral cortex (Figure 4a). At 81 dpi a few
small plaques were seen near the needle track in the ip-
silateral cortex, striatum, adjacent subependymal region
and corpus callosum (Figure 4b). At 160 dpi, plaques
were noted along the entire needle track in the cortex,
corpus callosum and striatum (Figure 4c). Additional
plaques were also noted in perivascular sites of gray
matter and in extracellular spaces of corpus callosum
near the needle track on the ipsilateral side. The first
plaque on the contralateral side was detected in the cor-
tex at 160 dpi (Figure 4c). At 213 dpi plaques were more
widely distributed on both sides of the brain in many
gray matter and white matter regions including the sub-
ependymal areas, but the ipsilateral side still had many
more plaques than the contralateral side (Figure 4d). At
320 dpi the plaque distribution was even wider, and the
two sides of the brain were nearly equal in distribution
and density of plaques (Figure 4e).
Even at the earliest time points, 40 and 81 dpi, the pla-
ques appeared to be associated with blood vessel walls
and adjacent perivascular areas in both gray matter and
white matter (Figures 4f- 4 h). Plaques in the subependy-
mal regions appeared to associate with both the
basal side of ependymal cells and with blood vessels
(Figure 4g). At all time-points from 40–336 dpi, plaques
were also seen in large white matter tracts such as the
corpus callosum, and plaques also appeared to occupy
extracellular periaxonal spaces (Figures 4h and 4i). In
gray matter, even at late times such as 336 dpi, the
smaller plaques on the contralateral side still maintained
a consistent pattern of association with small bloodvessels (Figure 4j), suggesting that perivascular spread
was a common feature throughout the disease course.
Thus, the timing and pattern of plaque distribution after
microinjection of tg44 mice with RML scrapie supported
our previous hypothesis that spread of infectivity oc-
curred via dissemination with brain interstitial fluid
(ISF) in perivascular regions of gray and white matter
and in interaxonal spaces of white matter tracts [31].
Vascular specificity at preclinical times after infection of
tg mice
We have previously described the association of PrPres
with capillaries, veins and arteries in tg44 mice at late
times in disease after injection with 50 μl volumes of
scrapie homogenate [31]. However, spread in these ex-
periments might have been influenced by CSF contamin-
ation at the time of injection. In the current experiments
we examined mice at earlier times after injection of
0.5 μl of scrapie to see whether PrPres was consistently
associated with blood vessels at early and late times after
microinjection. To confirm the association between
perivascular blood vessels and PrPres in tg44 mice at
preclinical times post-infection, brain tissues were
double-stained for PrPres and for the blood vessel anti-
gen, CD31, located in endothelial cell tight junctions of
capillaries, veins and arteries.
At 160 dpi tg44 mice had PrPres deposits associa-
ted with CD31-positive capillaries, arteries and veins
(Figure 5a). As noted previously, the majority of PrPres
was associated with capillaries, which were identified as
blood vessels by their staining with anti-CD31 and as ca-
pillaries by their small diameters (3–7 μm). However,
PrPres was also associated with larger vessels including
both veins and arteries (Figure 5a) [31]. Similar results
were seen at 81 dpi. This vascular PrPres distribution in
tg44 mice differed markedly from the pattern seen in
non-transgenic C57 mice expressing anchored PrP,
where PrPres was not in a perivascular location, but in-
stead tended to cluster around parenchymal cells with
large nuclei, possibly neurons or astroglia (Figure 5b), as
Figure 5 Detection of PrPres and blood vessels in tg44 and C57 mice at 160 days after microinjection of RML scrapie. Sections show
thalamus at a level 2–3 mm caudal to the needle track. Sections were stained with D13 to detect PrPres (red), with anti-CD31 to detect blood
vessel endothelial cells (green), and DAPI (blue) to detect nuclei. (a) In tg44 mouse dense PrPres plaques appear to associate with CD31-positive
vessels of various sizes. Two large veins (arrowheads) and several capillaries (arrows) are indicated. Erythrocytes in vessels show green autofluores-
cence. (b) In C57 mouse PrPres is diffuse and appears to be concentrated around possible neurons (arrows) with large DAPI- stained nuclei, rather
than around blood vessels (arrowheads). Scale is same in each panel, and bar represents 50 μm.
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supported our previous suggestion of a role for brain ISF
in moving small diffusible PrPres oligomers to blood
vessels where further conversion of new PrPres might be
promoted by the presence of scaffolding molecules in
basement membranes [31].
Focal pathology associated with PrPres plaques in tg44
mice
At the clinical endpoint (300–330 dpi) in tg44 mice we
previously found evidence of pathological changes
around deposits of PrPres amyloid, including astroglio-
sis, microgliosis, distortion of neuroanatomy by amyloid,
neuronal loss, white matter vacuolation, axonal dys-
trophy and deposition of amyloid precursor protein
(APP) [28]. In these studies it was not possible to iden-
tify the earliest pathological changes because mice were
examined only at the clinical timepoint. Therefore, in
the present work we studied mice microinjected with
scrapie at earlier times post-injection to attempt to iden-
tify the earliest pathological events. At 81 dpi, we found
significant numbers of activated microglia and astroglia
surrounding the newly formed PrPres plaques in stri-
atum and subependymal regions (Figures 6a- 6c). In
addition, morphological changes including vacuolation
of white matter, foamy gray matter parenchyma, and oc-
casional nuclear vacuoles, were also detected associated
with PrPres deposits at 81–160 dpi (Figures 6d- 6f ).
These findings also correlated with detection of APP de-
position associated with plaques (Figure 6g). However,
no significant TUNEL staining or apoptotic bodies could
be detected (not shown). Thus pathological abnormal-
ities associated with plaques at early preclinical times ininfected tg44 mice were similar to abnormalities seen
previously at 330–350 dpi at the clinical end-point [28].
Spread of scrapie infection in C57 mice expressing
anchored PrP by non-vascular pathways
As a control for the above experiments with tg44 mice,
C57 mice which express anchored PrP were also infected
with scrapie i.c. using the microinjection technique.
PrPres was detected in a non-amyloid diffuse form in
these mice and was first seen at the needle track in stri-
atum and corpus callosum at 40 dpi (Figure 7a), and
only minimal staining was seen in cortex ispilateral to the
needle track (Figure 7d). By 80 dpi, PrPres was seen in
the striatum and ipsilateral cortex at sites near and more
distant from the needle track (Figure 7b), as well as in
contralateral cortex (Figure 7e). At 150–160 dpi at the
clinical endpoint, PrPres was still visible near the needle
track scar (Figure 7c), and in the contralateral cortex
(Figure 7f ), as well as in many other regions on both
sides of the brain (not shown). This pattern of PrPres
distribution did not appear to follow the blood vessels
(Figure 5b) and was markedly different from the perivas-
cular plaque pattern seen in tg44 mice (Figures 4 & 5a).
In addition, the apparent rate of PrPres spread from
the inoculation site in striatum to thalamus at a level ap-
proximately 3 mm caudal to the needle track site was
much faster in C57 mice than in tg44 mice. In Figure 8
spread of PrPres to ipsilateral thalamus was detected at
40 dpi and spread to contralateral thalamus was seen at
80 dpi (Figures 8a & 8b). In contrast, in tg44 mice the
first detection of PrPres at this level was detectable in 1
of 3 mice at 160 dpi in cortex but not in thalamus
(Figure 8c), and was first seen in thalamus at 213 dpi
Figure 6 Neuropathology in scrapie-infected tg44 mice at preclinical times. (a-d) Panels show striatum and subependymal regions adjacent
to needle track at 81 dpi. (a) PrPres visualized by D13 staining. Arrowheads show subependymal plaques often associated with blood vessels
(arrows). On left side of field is a large plaque at the end of the needle track (bold arrow). (b) Staining with anti-Iba1 shows infiltration of microglia
and/or macrophages often with an activated morphology consisting of larger cell bodies and thickened processes. Subependymal (arrowheads)
and needle track (bold arrow) accumulations of cells correlate with PrPres plaques seen in (a). (c) Staining with anti-GFAP shows accumulation of
activated astroglia in areas of subependymal plaques (arrowheads) and needle track (bold arrow). (d) H&E staining of same field shown in (a-c).
In needle track area, arrows indicate small vacuoles in white matter of striatum. Near lower arrow hypercellularity and distorted architecture can
be seen. Arrowhead indicates a subependymal plaque. Apparent vacuolation of subependymal region is likely an artifact. (e) Perivascular PrPres
plaque in striatum of tg44 mouse at 160 dpi. A large vein (arrowhead) and prominent capillary (arrow) can be seen. (f) H&E staining of section in
same area as (e) shows white matter vacuoles (arrows) and two nuclei with apparent vacuoles (arrowheads). Inset shows higher magnification of
one nucleus with vacuoles. Large vein is indicated by larger arrowhead. (g) In striatum of same mouse shown in (e) and (f), double-staining
shows APP accumulation (green) associated with PrPres plaques (magenta) surrounding capillaries (arrows) and large vein (arrowhead). Scale is
same in panels a-d, and bar shown in (a) represents 50 μm. Other bars are as follows: e, 65 μm; f, 25 μm; g, 50 μm.
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striatum of C57 mice, the rapid spread of PrPres to thal-
amus and the cellular distribution within thalamus sug-
gested that spread followed neuroanatomical pathways
[35] rather than vasculature. In contrast, spread of
PrPres to thalamus in tg44 mice was much slower andappeared to maintain its typical association with blood
vessels as described above.
Discussion
In the present experiments tg44 mice expressing anchor-
less PrP and C57 mice expressing anchored PrP were
Figure 7 Detection of PrPres by D13 staining in non-transgenic C57 mice at various times after microinjection of RML scrapie in
striatum. (a) At 40 dpi punctate PrPres staining can be seen in needle track in striatum associated with larger cells (black arrowhead) and in
horizontally running axonal areas of corpus callosum at top of panel (arrow). Although blood vessels can be easily seen, there is minimal
association of PrPres with blood vessels (green arrowhead). At 80 dpi (b) and 150 dpi (c) PrPres associated with needle track remains punctate
and diffuse. (d) At 40 dpi in lateral cortex on ipsilateral side, there is faint PrPres staining (arrow) near outer surface of cortex. (e) At 80 dpi in
contralateral cortex, prominent accumulation of diffuse and punctate PrPres (arrow) can be seen associated with parenchymal cells. (f) At the
clinical disease end-point,150 dpi, diffuse and punctate PrPres occupies most of cortex. There is no obvious blood vessel association. NT: Needle
track, CTX: Cortex. Scale is same in each panel, and bar shown in (a) represents 100 μm.
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ing dilution i.c. infection using RML scrapie (Figure 1).
Therefore, the differences previously noted between
these mouse strains in scrapie incubation period, typesof clinical signs and neuropathology [28] are likely due
to factors other than susceptibility to infection. In tg44
mice the lack of carbohydrates and GPI anchor on
the anchorless PrP molecules as well as the lack of
Figure 8 Comparison of PrPres morphology at sites of secondary deposition in mid-thalamic region 3 mm caudal to the needle track
injection site in C57 versus tg44 mice at various times after scrapie microinjection. In C57 mice at 40 dpi (a) punctate PrPres is seen in
thalamus on ipsilateral side but not on contralateral side. Line denotes middle of brain separating the two sides. Most PrPres is accumulated
around cells with visible round nuclei (arrow). (b) At 80 dpi in a C57 mouse PrPres was detected on both sides of brain in thalamus, again mostly
around cells with large nuclei (arrow). (c) At 160 dpi in tg44 mice no PrPres was detected at this level in thalamus. However, one perivascular
plaque was seen in cortex in 1 of 3 mice (inset). (d) At 213 dpi in tg44 mice several PrPres plaques were seen in thalamus on both sides of brain.
At higher power PrPres appeared to be concentrated around capillaries (arrowheads) and larger vessels (arrow). Scale is same in each panel, and
bar shown in (a) represents 100 μm.
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to contribute to an increased susceptibility to amyloid for-
mation during the generation of PrPres [8,36]. However, it
is less clear whether the amyloid and non-amyloid forms
of PrPres might differ in their neurotoxic potential. Fur-
thermore, the cell surface expression of anchored PrPsen
might also be an important factor in susceptibility of cells
and tissues to toxic effects induced by PrPres and/or by
disease-induced factors other than PrPres.
In addition to the actual mechanisms of brain damage
induced by local prion infection and accumulation of
PrPres, the ability of prion infectivity to spread within
the brain would also be expected to influence the timing
of clinical onset. Because of the slow course of prion in-
fection, it might take significant time to spread the infec-
tion to brain areas vital for survival, such as brain stem
and midbrain, where production of sufficient PrPres and
other toxic products to induce significant dysfunction
would also be required. Thus, in tg44 mice the long in-
cubation period might also be due to slow spread from
the site of injection to the rest of the CNS. In the
present experiments, to measure spread of prions in
tg44 and C57 mice, we used microinjection of scrapie
infectivity in a 0.5 μl volume over 2 minutes to deposit
the infectivity in the striatum with minimal leakage and
dispersion via the CSF. With this method in tg44 micePrPres was detected first at the injection site at 40 dpi
and subsequently spread progressively to the rest of the
brain over a total of 336 dpi (Figures 4a- 4e). The pat-
tern of sequential IHC detection of PrPres indicated that
the spread proceeded by following mostly along the peri-
vascular regions of capillaries, arteries and veins in both
gray and white matter, but also along interaxonal spaces
in white matter tracts and in subependymal regions near
ventricles (Figure 4f-j). In experiments using tracers of
the brain ISF, all of these areas have been reported to be
sites of ISF drainage [29,37-39]. Therefore our results
suggested an important association between ISF drain-
age and PrPres amyloid deposition. Furthermore, PrPres
association with ISF drainage areas was observed at
40-81 dpi, which was also the earliest times of PrPres
detection (Figures 4f-h, and 5a). Thus the association of
PrPres with the ISF drainage system was not merely a
finding late in the disease process, but rather was an
early event which might be important in the dissemin-
ation of PrPres through the brain. These results ap-
peared to exclude the possibility that in microinjected
mice dispersion of PrPres seeds occurred only at the
time of initial injection, which was one possibility pro-
posed in the introduction to this paper.
In our current experiments using microinjection of
scrapie infectivity into C57 mice, spread of PrPres within
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mice we detected spread of PrPres from striatum to ipsi-
lateral thalamus by 40 dpi (Figure 8a) and crossover to
the contralateral thalamus by 80 dpi (Figure 8b). This
spread was much faster and the distance covered was
much greater (3 mm from striatum to thalamus) than
the limited PrPres spread detected in tg44 mice. In
addition, in C57 mice there was minimal association of
PrPres with blood vessels, but instead PrPres in C57
mice appeared to be concentrated around cells with
medium to large nuclei which appeared to be neurons
(Figure 5b). This localization and speed of spread was
consistent with evidence from other experiments that in
mice expressing anchored PrP scrapie could be trans-
ported rather rapidly along neurons following neuroana-
tomical pathways [9,35,40]. Thus, the differences in
tempo and mechanisms of PrPres spread in tg44 versus
C57 mice might contribute to the large difference in
time of clinical onset in these two mouse strains.
Interestingly the pathological processes responsible for
clinical scrapie disease are not identical in mouse strains
differing in expression of anchored PrP [28], and these
differences might also influence the timing of clinical
disease onset. After scrapie infection, both tg44 mice
and C57 mice have prominent astrogliosis and micro-
gliosis. However, C57 mice have gray matter vacuolation
together with deposition of non-amyloid PrPres in a dif-
fuse pattern. In contrast, tg44 mice have perivascular
deposition of PrPres in an amyloid form leading to cere-
bral amyloid angiopathy (CAA). Tg44 mice also show
high amounts of APP co-localizing with PrPres suggest-
ing axonal dystrophy, and they have prominent vacuol-
ation of white matter, but not gray matter, suggesting a
different type of brain damage than seen in typical prion
disease. In the present experiments, from 81–160 dpi we
found gliosis, white matter vacuolation and detection of
APP associated with PrPres plaques in tg44 mice. This
pathology was similar to the pathology previously de-
scribed in clinical disease in these mice [28]. Thus,
although local damage detected took less than 3 months
to occur, 11–12 months was required for clinical onset,
and this additional time might reflect the necessity for
gradual spread of the infection and the pathology to
wider areas of the CNS.
The present time-course experiments demonstrated
slow spread of PrPres plaque deposition and related
neuropathology associated with the ISF drainage system.
A role for the ISF system in PrPres deposition in tg44
mice was first suggested by our earlier findings that
PrPres deposits found at the clinical endpoint were
associated with microinjected ISF tracers such as FITC-
ovalbumin [29]. PrPres deposits were subsequently
found to be associated with capillaries, arteries and veins
in tg44 mice starting at the basement membrane [31].Possibly basement membrane components, such as lam-
inin or glucosaminoglycans, might bind small diffusible
PrPres oligomers found in the extracellular fluid causing
these oligomers to be concentrated and possibly assem-
bled in ordered aggregates, thus facilitating their conver-
sion to PrPres. Such a scaffolding mechanism might be
more important for soluble anchorless PrP found in
extracellular fluid compared to normal membrane-
anchored PrP, which exists naturally in a partially
concentrated array on the cellular plasma membrane.
Finding of amyloid PrPres and associated pathology as
early as 81 dpi in infected tg44 mice indicated that these
processes proceed at a tempo nearly 4 times faster than
the development of clinical signs, suggesting that the
slow tempo of the clinical disease development is mainly
due to the slow spread of the pathology to the rest of
the brain.
Spread of PrPres via the ISF might also explain finding
of PrPres mostly on meningeal and ependymal surfaces
in tg44 mice injected i.c. with 50 μl volumes of highly di-
luted scrapie (Figure 2c and d). In this experiment the
initial injection was probably distributed in large part via
the CSF to meninges and ependyma. However, in most
places the PrPres failed to penetrate from these sites
deeper into the parenchyma, and this might be because
the direction of ISF drainage flow is mainly along the
perivascular regions going from the deeper brain areas
towards the leptomeningeal areas where this flow ultim-
ately exits the brain to enter the deep cervical lymph
nodes [38,39].
In humans and animals expressing GPI-anchored PrP,
spread of PrPres in both the CNS and peripheral ner-
vous system appears to occur by following neuronal
pathways [9,10,14,15,40]. In C57 mice we found a similar
neuronal pattern of spread within the CNS after local
microinjection of scrapie into the striatum. In our previ-
ous experiments using retinal injection of scrapie in a
2 μl volume, transgenic mice expressing anchored PrP
only in neurons (tgNSE) showed spread of PrPres from
retina to brain following the optic system, whereas mice
expressing anchored PrP only in astrocytes (tgGFAP)
showed very slow spread by a random cell-to-cell diffus-
ing mechanism not involving nerves or blood vessels
[17]. These data together with the present data in tg44
mice suggest that anchorless PrP was not sufficient for
neuron-mediated spread of scrapie within the CNS and
that presence of GPI-anchored PrP on neurons was
probably required. The mechanism of neuron-mediated
scrapie spread is not known, but its speed has been esti-
mated to range from 0.5 to 3.3 mm/day [9,40,41], which
is much slower than typical retrograde axonal transport,
whose rate is from 85–430 mm/day [42]. In addition,
conditions which hamper retrograde axonal transport
such as overexpression of four-repeat tau, do not block
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infectious prions along nerves probably involves a differ-
ent type of mechanism [44,45]. Discovery of the details
of this process should provide new approaches to con-
trol of clinical prion diseases in humans.
In humans four different mutations encoding PrP with
a C-terminal truncation and lacking the GPI anchor
(Y145X, Q160X, Y163X, and Y226X) have been discov-
ered in patients with fatal neurodegenerative disease
associated with perivascular amyloid PrPres deposition
and CAA neuropathology similar to that seen in scrapie-
infected tg44 mice [22-25]. Therefore, the lack of the GPI
anchor might be important for development of this
pathology. However, in an additional patient expressing
anchorless PrP (Q227X), multicentric PrPres amyloid pla-
ques were seen without evidence for CAA pathology [23].
Perhaps this mutant PrP is actually membrane bound by a
mechanism not involving GPI, or alternatively, factors
other than membrane binding of PrP might also be in-
volved in promoting the generation of CAA.
The mechanism of spread of PrPres amyloid is not
clear in any of these patients, but the similarity of the
late stage pathology to our results in tg44 mice suggests
that spread of amyloid conversion along the ISF drainage
pathway might occur as a result of the secretion of an-
chorless PrP. Possibly pathogenic mechanisms similar to
those seen in tg44 mice [28] might be involved in the
tissue damage in these humans. CAA is also an import-
ant aspect of the pathology and pathogenesis of Alzhei-
mer’s disease in humans, and the ISF drainage system
might play a role in the spread of Aβ amyloid in this dis-
ease [46]. Thus scrapie-infected tg44 mice may provide a
good animal model for study of mechanisms leading to
CAA in both familial prion disease and Alzheimer’s dis-
ease. Further studies will be required to determine the
details of the pathogenesis in both the human and ani-
mal systems.
Conclusions
In scrapie-infected mice with anchored PrP, the disease-
associated PrPres generated was mainly non-amyloid in
structure and appeared to spread via neurons to distant
connected brain areas where additional PrPres was
generated by the clinical endpoint at 150 days post-
inoculation. This PrPres was rarely associated with blood
vessels. In contrast, in mice with anchorless PrP, PrPres
was mostly in the amyloid form and spread did not fol-
low neuronal circuitry, but instead followed a novel
slower pattern utilizing the drainage system of the brain
interstitial fluid (ISF) including perivascular areas adja-
cent to blood vessels, subependymal areas and spaces
between axons in white matter tracts. The mechanism
of spread of PrPres amyloid in transgenic mice express-
ing anchorless PrP appeared to be transport of smallamyloid-seeding PrPres aggregates in the ISF, thus pro-
moting the development of cerebral amyloid angiopathy
throughout the brain. Spread of amyloid seeding by ISF
may also occur in multiple human brain diseases involv-
ing cerebral amyloid angiopathy.
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